Skip to content
MARKETS / NASDAQ / PRFX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

PRF Technologies Ltd. PRFX

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$17,000
$-5.0M
$-4.0M
In brief

What this company does

Our proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. In March 2025, we acquired the business operations related to an AI-driven solar analytics technology, DeepSolar. We were incorporated under the laws of the State of Israel the Companies Law in November 2007 under the name PainReform Ltd. On January 6, 2026, the shareholders of the Company approved a change of the Company’s name from PainReform Ltd. to PRF Technologies Ltd. Our strategy is to incorporate generic drugs with our proprietary extended-release drug-delivery system in order to create extended release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the FDA.

Written from the business description in PRF Technologies Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth
USD 17,000.00
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -5.0
-5M-10M20182019202020212022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−29541 cents
lost on every revenue dollar
ROE
FY2025 · ROE -96.9%
-100%-200%-300%20182019202020212022202320242025
Gross margin-311.8%
Operating margin-30129.4%
Net margin-29541.2%
Return on assets-60.8%
EBITDAUSD -5.1M

Each USD of equity lost 97 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -4.0
-5M-10M20182019202020212022202320242025

Total assetsUSD 12.0M
EquityUSD 8.5M
CashUSD 3.1M
Current ratio1.78×

Equity funds 71% of total assets.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018
Revenue $B0.00.00.0·····
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0·−0.0·
Income tax $B0.00.00.00.00.00.00.0·
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
EPS, diluted $−7.47−105.52−122.94−63.46−7.25−1.25−4.17−3.24
Dividend / sh $········
Payout %········
ROE %−96.9−321.9−102.3−60.4−41.8−185.2··
Shares out B0.000.000.000.000.010.010.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 30 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2018

Share this section

Download image